Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +2.17%90 ROC (Joel Greenblatt) % is 20.35% as of Jun. 2026, which is 41% below its 10-year median of 34.43. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,736.93 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,322 Biotechnology companies, Concord Biotech ranks better than 87.59% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Concord Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 20.35%.
The historical rank and industry rank for Concord Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:543960'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 22.98 Med: 34.43 Max: 42.28
Current: 24.8
During the past 7 years, Concord Biotech's highest ROC (Joel Greenblatt) % was 42.28%. The lowest was 22.98%. And the median was 34.43%.
BOM:543960's ROC (Joel Greenblatt) % is ranked better than 87.59% of 1322
companies
in the Biotechnology industry
Industry Median: -314.45
vs BOM:543960: 24.80
Concord Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -5.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Concord Biotech ROC (Joel Greenblatt) % Related Terms
Concord Biotech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, MRNA: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Concord Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 20.35% mean?
Concord Biotech (BOM:543960) has a ROC (Joel Greenblatt) % of 20.35% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Concord Biotech and its competitors. This is 41% below median its historical median of 34.43. Over the past decade, Concord Biotech's ROC (Joel Greenblatt) % has ranged from 22.98 to 42.28. According to the industry distribution chart, Concord Biotech ranks #164 out of 1322 companies in the Biotechnology industry, placing it in the top 12.4%.
Is Concord Biotech's ROC (Joel Greenblatt) % too high?
Concord Biotech's current ROC (Joel Greenblatt) % of 20.35% is 41% below median its 10-year median of 34.43. Over the past 10 years, this metric has ranged from a low of 22.98 to a high of 42.28. Based on the distribution chart, Concord Biotech ranks #164 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #164 out of 1322 companies for ROC (Joel Greenblatt) %. This places Concord Biotech in the top 12% of its industry — outperforming the majority of peers. Historically, Concord Biotech's own ROC (Joel Greenblatt) % has ranged from 22.98 to 42.28 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Concord Biotech and its competitors. Concord Biotech's current ROC (Joel Greenblatt) % is 20.35%, which is 41% below median its own 10-year median of 34.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,736.93, compared to a current price of ₹1,493.90 — trading 14% below its estimated fair value. The current ROC (Joel Greenblatt) % is 20.35%, which is 41% below median its 10-year median of 34.43. Concord Biotech's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current ROC (Joel Greenblatt) % is 20.35% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,493.90 is trading 14% below its estimated GF Value™ of ₹1,736.93.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
ROC (Joel Greenblatt) %: 20.35% (41% below median its 10-year median of 34.43)
GF Value™: ₹1,736.93 vs. price of ₹1,493.90 (14% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score
Get the complete analysis for BOM:543960
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
